

# **Evaluation of Serum Midkine as a Marker of Hepatocellular Carcinoma in Cirrhotic Egyptian Patients**

*A Thesis*

*For Partial Fulfillment of Master Degree in  
Internal Medicine*

*By*

**Mohamed Ramadan Osman**

*Bachelor Degree in Medicine and Surgery Ain Shams University*

*Supervised by*

**Prof.Dr. Noha Abdelrazek Elnakeeb**

*Professor of Internal Medicine and Gastroenterology  
Faculty of medicine – Ain Shams University*

**Assist.Prof.Dr.Ahmed El Saady Mohammed Khayyal**

*Assistant Professor of Internal Medicine and Gastroenterology  
Faculty of medicine – Ain Shams University*

**Dr. Ahmed Mohamed El Ghandour**

*Lecturer of Internal Medicine and Gastroenterology  
Faculty of medicine – Ain Shams University*

*Faculty of Medicine  
Ain Shams University*

**2018**

# Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Moha Abdelrazek Elnaakeeb**, Professor of Internal Medicine and Gastroenterology Faculty of medicine – Ain Shams University for her keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Assist. Prof. Dr. Ahmed El Saady Mohammed Khayyal**, Assistant Professor of Internal Medicine and Gastroenterology Faculty of medicine – Ain Shams University, for his kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr. Ahmed Mohamed El Ghandour**, Lecturer of Internal Medicine and Gastroenterology Faculty of medicine – Ain Shams University, for his great help, active participation and guidance.*

**Mohamed Ramadan**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

﴿وَعَلَّمَكَ مَا لَمْ تَكُنْ تَعْلَمُ وَكَانَ

فَضْلُ اللَّهِ عَلَيْكَ عَظِيمًا﴾

صدق الله العظيم  
سورة النساء آية (١١٣)

# *List of Contents*

Title	Page No.
List of Tables .....	5
List of Figures .....	6
List of Abbreviations .....	8
Introduction .....	1
Aim of the Work .....	13
Review of Literature	
▪ Hepatocellular Carcinoma .....	14
▪ Midkine .....	68
Patients and Methods .....	91
Results .....	96
Discussion .....	113
Summary .....	120
Conclusion .....	122
Recommendations .....	123
References .....	124
Arabic Summary .....	—

## *List of Tables*

Table No.	Title	Page No.
<b>Table (1):</b>	Actions of MK to cultured cells. ....	72
<b>Table (2):</b>	Descriptive analysis of the studied population as regard the age. ....	96
<b>Table (3):</b>	Comparison between the three groups as regards the gender. ....	97
<b>Table (4):</b>	Comparison between the three groups as regards the smoking status. ....	97
<b>Table (5):</b>	Child Pugh classification among HCC group. ....	98
<b>Table (6):</b>	Comparison between group I and II as regards modified Child Pugh score. ....	99
<b>Table (7):</b>	Barcelona clinic liver cancer staging system (BCLC) classification among HCC group. ....	99
<b>Table (8):</b>	Portal vein invasion among HCC group. ....	100
<b>Table (9):</b>	Comparing the three groups regarding the laboratory data. ....	102
<b>Table (10):</b>	Correlation between Midkine and all other parameters in group I. ....	103
<b>Table (11):</b>	Comparison between the three groups as regards alpha-fetoprotein. ....	104
<b>Table (12):</b>	Comparison between the three groups as regards serum Midkine level. ....	105
<b>Table (13):</b>	Correlation between Midkine and number of HCC lesions. ....	107
<b>Table (14):</b>	Correlation between Midkine and different BCLC stages. ....	109
<b>Table (15):</b>	Correlation between Midkine and portal vein invasion. ....	110
<b>Table (16):</b>	Correlation between Midkine and Child Pugh score classification. ....	110
<b>Table (17):</b>	ROC curve between group A and group B. ....	112

## *List of Figures*

Fig. No.	Title	Page No.
<b>Figure (1):</b>	AASLD algorithm for investigation of small nodules found on screening in patients at risk for hepatocellular carcinoma.....	29
<b>Figure (2):</b>	Diagnostic algorithm and recall policy of HCC .....	32
<b>Figure (3):</b>	Triple phase CT scanning of Hepatocellular carcinoma .....	35
<b>Figure (4):</b>	Magnetic resonance (MR) imaging of the liver performed in a 73-year-old man with hepatitis C and cirrhosis, and a newly diagnosed hepatocellular cancer.....	36
<b>Figure (5):</b>	Growth patterns of progressed hepatocellular carcinoma .....	55
<b>Figure (6):</b>	Modified Barcelona Clinic Liver Cancer (BCLC) staging system.....	57
<b>Figure (7):</b>	Primary structure of human MK.....	69
<b>Figure (8):</b>	Binding of heparin sulfate trisulfated unit and chondroitin sulfate E unit to C-domain of human MK .....	70
<b>Figure (9):</b>	Binding of heparan sulfate trisulfated unit and chondroitin sulfate E unit to C-domain of human MK .....	73
<b>Figure (10):</b>	A proposed model of MK action.....	74
<b>Figure (11):</b>	Child classification among HCC group.....	98
<b>Figure (12):</b>	Different BCLC stages among HCC group patients.....	100
<b>Figure (13):</b>	Shows Portal Vein invasion among HCC group. ....	101
<b>Figure (14):</b>	Comparison between the three groups as regards alpha fetoprotein showing higher level in HCC group more than liver cirrhosis and healthy groups. ....	104

## *List of Figures Cont...*

Fig. No.	Title	Page No.
<b>Figure (15):</b>	Comparison between the three groups as regards serum Midkine level showing higher level in HCC group more than liver cirrhosis and healthy groups. ....	105
<b>Figure (16):</b>	Number of focal lesions in patients with HCC group I. ....	106
<b>Figure (17):</b>	Correlation between midkine and number of HCC lesions showing a positive correlation. ....	108
<b>Figure (18):</b>	Correlation between Midkine and tumor size showing positive correlation between them as regards the tumor size .....	108
<b>Figure (19):</b>	Correlation between Midkine and different BCLC stages showing no significant difference between BCLC staging and midkine level. ....	109
<b>Figure (20):</b>	Correlation between AFP and size of focal lesion showing a positive significant correlation. ....	111
<b>Figure (21):</b>	Correlation between AFP and numbers of focal lesions. ....	111
<b>Figure (22):</b>	ROC curve of serum midkine between group A and group B. ....	112

## *List of Abbreviations*

Abb.	Full term
<i>5`-NPD</i> .....	<i>5`-Nucleotide phosphodiesterase</i>
<i>8-OHDG</i> .....	<i>8-hydroxydeoxyguanosine</i>
<i>AASLD</i> .....	<i>American Association for the Study of Liver Disease</i>
<i>AFP</i> .....	<i>Alfa feto protein</i>
<i>AFPL3</i> .....	<i>Agglutinin reactive AFP</i>
<i>AFU</i> .....	<i>Alpha L-Fucosidase</i>
<i>Alb</i> .....	<i>Albumin</i>
<i>ALP</i> .....	<i>Alkaline phosphatase</i>
<i>ALT</i> .....	<i>Alanine aminotransferase</i>
<i>AST</i> .....	<i>Aspartate aminotransferase</i>
<i>BCLC</i> .....	<i>Barcelona Clinic Liver Cancer</i>
<i>BUN</i> .....	<i>Blood urea nitrogen</i>
<i>CEA</i> .....	<i>Carcinoembryonic Antigen</i>
<i>CLIP</i> .....	<i>Cancer of the Liver Italian Program</i>
<i>CT</i> .....	<i>Computed tomography</i>
<i>CUPI</i> .....	<i>Chinese University Prognostic Index</i>
<i>CYFRA21-1</i> .....	<i>Cytokeratin 19 fragment</i>
<i>D.Bil</i> .....	<i>Direct bilirubin</i>
<i>DCP</i> .....	<i>Des-<math>\gamma</math>-carboxy prothrombin</i>
<i>EASL</i> .....	<i>European Association for the Study of the Liver</i>
<i>ECG</i> .....	<i>Electrocardiogram</i>
<i>ELISA</i> .....	<i>Enzyme Linked Immunosorbent assay</i>
<i>GGT</i> .....	<i>Gamma glutamyl transpeptidase</i>
<i>GP73</i> .....	<i>Golgi protein-73</i>
<i>HBsAg</i> .....	<i>Hepatitis B surface antigen</i>
<i>HBV</i> .....	<i>Hepatitis B virus</i>



## *List of Abbreviations Cont...*

Abb.	Full term
<i>HCC</i> .....	<i>Hepatocellular carcinoma</i>
<i>HCV</i> .....	<i>Hepatitis C virus</i>
<i>HDV</i> .....	<i>Hepatitis D virus</i>
<i>HGF</i> .....	<i>Hepatocyte growth factor</i>
<i>HNE</i> .....	<i>4-hydroxynonenal</i>
<i>HRP</i> .....	<i>Horseradish Peroxidase</i>
<i>HSP</i> .....	<i>Heat shock protein</i>
<i>ICC</i> .....	<i>Intrahepatic cholangiocarcinoma</i>
<i>IGF</i> .....	<i>Insulin-like growth factor</i>
<i>IGF-2</i> .....	<i>Insulin Growth Factor-2</i>
<i>IGF-II</i> .....	<i>Insulin-like growth factor-II</i>
<i>IL-8</i> .....	<i>Interleukin-8</i>
<i>INR</i> .....	<i>International normalization Ratio</i>
<i>JIS</i> .....	<i>Japan Integrated Staging</i>
<i>LCSGJ</i> .....	<i>Liver Cancer Study Group of Japan</i>
<i>MAGE-1</i> .....	<i>Melanoma antigen gene</i>
<i>MDK</i> .....	<i>Midkine</i>
<i>MFP</i> .....	<i>Medial floor plate</i>
<i>MR</i> .....	<i>Magnetic resonance</i>
<i>MRI</i> .....	<i>Magnetic resonance imaging</i>
<i>MWA</i> .....	<i>Microwave ablation</i>
<i>Na</i> .....	<i>Sodium</i>
<i>NAFLD</i> .....	<i>Non alcoholic fatty liver disease</i>
<i>OLT</i> .....	<i>Orthotopic liver transplantation</i>
<i>OS</i> .....	<i>Overall survival</i>
<i>PDGFR-beta</i> .....	<i>Platelet-derived growth factor receptor beta</i>
<i>PET</i> .....	<i>Positron emission tomography</i>
<i>PIVKA</i> .....	<i>Prothrombin induced by vitamin K absence</i>

## *List of Abbreviations Cont...*

Abb.	Full term
<i>PT</i> .....	<i>Prothombin time</i>
<i>PTP</i> ζ.....	<i>Phosphatase-ζ</i>
<i>PTT</i> .....	<i>Partial thromboplastin time</i>
<i>Raf/MEK/ERK</i> ...	<i>Raf/mitgen-activated protein kinase /extracellular signal-regulated kinase</i>
<i>RFA</i> .....	<i>Radiofrequency ablation</i>
<i>SCCA</i> .....	<i>Serum squamous cell carcinoma antigen</i>
<i>SHARP</i> .....	<i>Sorafenib HCC assessment randomised Protocol</i>
<i>SU</i> .....	<i>Sunitinib malate</i>
<i>T.Bil.</i> .....	<i>Total bilirubin</i>
<i>TACE</i> .....	<i>Trans arterial chemoembolization</i>
<i>TGF-β1</i> .....	<i>Transforming growth factor-beta 1</i>
<i>TIS</i> .....	<i>Taipei Integrated Scoring System</i>
<i>TKs</i> .....	<i>Tyrosine kinases</i>
<i>US</i> .....	<i>Ultrasonography</i>
<i>VEGF</i> .....	<i>Vascular Endothelial Growth Factor</i>
<i>VIP</i> .....	<i>Vasoactive intestinal peptide</i>

## INTRODUCTION

**H**epatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer-related deaths. The number of deaths per year for HCC worldwide is similar to the incidence, with nearly 748300 new cases and 695900 deaths per year. HCC most often develops in patients with a history of cirrhosis due to chronic alcohol abuse, non-alcoholic fatty liver disease, or hepatitis C virus (HCV) infection (*Izumi, 2010*).

Biomarkers that distinguish HCC from inflammation and cirrhosis are desperately needed in order to enhance prognosis of these patients.

Contributing to the poor prognosis of HCC is the lack of specific symptoms in the early stages of the disease. More than 60% of patients are diagnosed with late-stage disease after metastasis has occurred (*Altekruse, 2009*), resulting in an overall 5-year survival rate of  $< 16\%$  (*Siegel, 2013*). In contrast, patients diagnosed with early stage disease have a relatively good prognosis, with a 5-year survival rate of  $> 70\%$  (*Takayama et al., 2008*).

The diagnosis of HCC without a pathological diagnosis can be achieved by assessing serum  $\alpha$ -fetoprotein (AFP) levels and diagnostic imaging, such as computed tomography (CT) and magnetic resonance imaging (MRI) (*Aghoram et al., 2012*).

The ideal HCC biomarker is one that enables clinicians to diagnose asymptomatic patients and can be widely used in a screening process. In general, a biomarker valuable for clinical use achieves a level of sensitivity and specificity of  $\geq 90\%$ , and is non-invasive and cost-effective to allow widespread use. The most desirable biomarker is therefore tumor-specific and easily detectable in bodily fluids, such as serum, plasma, and bile (*Pepe, 2001*).

Midkine (MDK) is a heparin-binding growth factor that has been associated with tumor migration and proliferation (*Muramatsu, 2010*). Not surprisingly, MDK is often overexpressed in various human tumors, making it an attractive target in tumor detection and treatment (*Muramatsu, 2002*). A clinical study on a cohort of 388 HCC patients and 545 hospital enrollees diagnosed with other diseases identified MDK as a discriminating tissue and serum biomarker with better sensitivity (86.9%, serum MDK) than AFP (51.9%) (*Zhu, 2013*).

## **AIM OF THE WORK**

**T**o evaluate serum Midkine as a marker for Hepatocellular carcinoma in cirrhotic Egyptian Patients.

## *Chapter 1*

# **HEPATOCELLULAR CARCINOMA**

**H**epatocellular carcinoma (HCC) is the fifth most common malignancy and the second leading reason of cancer-associated deaths around the world, and more than 600,000 deaths are reported internationally each year (*Ferlay et al., 2015*). HCC takes up 85%–90% of primary liver cancers with 500,000 new cases of HCC all over the world every year (*Bozkaya et al., 2012*).

Incidence rates of the disease are increasing globally. In the United States, the incidence has doubled over the past 20 years (*El-Serag et al., 2014*).

The risk for HCC is influenced by etiology, activity, and stage of underlying liver disease. Patients with liver cirrhosis due to chronic infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) have the highest risk. The rising incidence in Western countries is mainly due to the still high prevalence of HCV-associated liver cirrhosis and the increasing number of patients with advanced steatohepatitis as hepatic manifestation of the metabolic syndrome (*El-Serag et al., 2014*).

Several reports indicate that HCC in the setting of metabolic syndrome may also arise in the absence of cirrhosis; however, the exact proportions of this condition or its risk factors are still under investigation (*Younossi et al., 2015*).

The main reasons for the high mortality rate of HCC patients are ascribed to the lack of effective treatments and the increasing resistance to conventional radiotherapy and chemotherapy (*Whittaker et al., 2010*).

Despite substantial progress in understanding of the molecular pathogenesis of HCC, imaging techniques, and novel therapies (including targeted drugs), the overall prognosis of HCC patients is still poor. Tumor multiplicity, frequent vascular invasion, and accompanying cirrhosis are clinical features of HCC that lead to unsatisfactory outcomes. High rates of tumor recurrence and resistance to chemotherapeutic agents also make the management of HCC challenging. The poor outcome of patients with HCC is attributed to late detection, with more than two-thirds of patients diagnosed at advanced stages of the disease (*Stravitz et al., 2008*). However, a considerable improvement in survival has been observed (5-year survival up from 40% to 70%) when patients are diagnosed at an early stage and receive potentially curative therapy in the form of liver transplantation, surgical resection, or tumor ablation (*Liu et al., 2004*).

## **Epidemiology**

Liver cancer in men is the fifth most frequently diagnosed cancer worldwide. In women, it is the seventh most commonly diagnosed cancer and the sixth leading cause of cancer death. In the United States, liver cancer is the ninth